<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835341</url>
  </required_header>
  <id_info>
    <org_study_id>CPDHS-434</org_study_id>
    <nct_id>NCT00835341</nct_id>
  </id_info>
  <brief_title>Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia</brief_title>
  <official_title>A Cohort Study on Prediction of Malignant Transformation of Oral Epithelial Dysplasia by p16 Methylation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral epithelial dysplasia (OED) is one of the common precancerous lesions among Chinese
      adults. Biomarker is not available for detection of malignant potential of OED till now. p16
      is an important tumor suppressor gene, which is inactivated frequently by methylation of CpG
      island in early stage of carcinogenesis. The present cohort study is to investigate whether
      p16 methylation is correlated with malignant transformation of OED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background: Identification of malignant potential of oral epithelial dysplasia (OED) is
           virtually impossible on histopathological grounds alone. Inactivation of p16 gene by CpG
           methylation is an early frequent event during oral carcinogenesis. To investigate the
           predictive value of p16 methylation on malignant potential in OED, we carried out the
           prospective cohort study.

        -  Methods: 101 patients with histologically confirmed mild or moderate OED were included
           in the present study. Baseline information of p16 methylation status of the OED lesions
           from 93 cases was obtained by methylation-specific PCR. Progression of the OEDs lesions
           was examined in 78 cases histologically during the 45.8 months double-blind followup
           survey (78/93). The association between p16 methylation and progression of OED was
           analyzed with SPSS13.0 software. All P-values were two-sided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia</measure>
    <time_frame>from 3 months to 124 months</time_frame>
    <description>The follow-up examination was carried out with a 3-month interval. Re-biopsy was done as clinically indicated, e.g. the lesion recurs or has tendency for malignant development. Pathologic diagnosis was made by at least two pathologists without the knowledge of baseline p16 methylation, based on the World Health Organization's criteria, at Peking University School of Stomatology. The number of participants with malignant transformation of oral dysplasia was calculated based on the number of participants with oral dysplasia progressed to carcinoma by the end of the trial in each cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-free Survival Time for Patients With Oral Epithelial Dysplasia</measure>
    <time_frame>from 3 months to 124 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">93</enrollment>
  <condition>Oral Epithelial Dysplasia, Mild or Moderate Grade</condition>
  <arm_group>
    <arm_group_label>p16-methylated</arm_group_label>
    <description>patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>p16-unmethylated</arm_group_label>
    <description>patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue specimen are collected from outpatients and inpatients with oral leukoplakia by biopsy
      or surgical resection, fixed in neutral buffered formalin, and embedded in paraffin. Genomic
      DNA is extracted from tissue sections.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        101 patients with mild or moderate OED were selected from cases with oral leukoplakia,
        lichen planus, or chronic discoid erythematosus at Peking University School of Stomatology
        between 1995 and 2005. All of the patients with OED had been diagnosed pathologically by at
        least two senior pathologists using the criteria from '2005 WHO Classification System'
        (Gale et al, 2005). All cases involved primary lesions without any LASER, radiation therapy
        or chemotherapy. p16 methylation status of OED samples was analyzed with
        methylation-specific PCR combined with denatured high performance liquid chromatography
        (Sun et al, 2004). 93 eligible cases with p16-methylated or p16-unmethylated OED were
        enrolled into the cohort study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of mild or moderate grade OED; and

          -  enough amount of tissue sample from OED lesion for genomic DNA extraction; and

          -  available of methylation status of p16 CpG island in the extracted DNA sample.

        Exclusion Criteria:

          -  histological diagnosis of severe grade OED or malignant disease; or

          -  amount of tissue sample is not enough for preparation of genomic DNA (20ng); or

          -  quality of the prepared DNA is not good enough for detection of p16 methylation; or

          -  OED treatment history by LASER, radiotherapy, or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dajun Deng, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital/ Institue, Peking University School of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hongwei Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University School of Stomatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oral Medicine, Peking University School and Hospital of Stomatology</name>
      <address>
        <city>Beijing</city>
        <zip>100081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.bjcancer.org</url>
    <description>Beijing Cancer Hospital/ Institute, Peking University School of Oncology</description>
  </link>
  <link>
    <url>http://ss.bjmu.edu.cn</url>
    <description>Peking University School of Stomatology</description>
  </link>
  <reference>
    <citation>Gale N, Westra W, Pilch BZ, et al. Epithelial precursors lesions. In: Barnes L, Eveson JW, Reichart P, et al. eds. World Health Organization Classification of Tumors: Pathology and Genetics of Head and Neck Tumors. IARC Press, Lyon (France); 2005: 177-179.</citation>
  </reference>
  <reference>
    <citation>Sun Y, Deng D, You WC, Bai H, Zhang L, Zhou J, Shen L, Ma JL, Xie YQ, Li JY. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin Cancer Res. 2004 Aug 1;10(15):5087-93.</citation>
    <PMID>15297411</PMID>
  </reference>
  <results_reference>
    <citation>Cao J, Zhou J, Gao Y, Gu L, Meng H, Liu H, Deng D. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin Cancer Res. 2009 Aug 15;15(16):5178-83. doi: 10.1158/1078-0432.CCR-09-0580. Epub 2009 Aug 11.</citation>
    <PMID>19671846</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>October 21, 2009</results_first_submitted>
  <results_first_submitted_qc>February 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2010</results_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Dajun Deng</investigator_full_name>
    <investigator_title>Professor and Department Director</investigator_title>
  </responsible_party>
  <keyword>oral epithelial dysplasia</keyword>
  <keyword>p16 methylation</keyword>
  <keyword>prognosis</keyword>
  <keyword>malignant transformation</keyword>
  <keyword>oral squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>p16-methylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.</description>
        </group>
        <group group_id="P2">
          <title>p16-unmethylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>p16-methylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.</description>
        </group>
        <group group_id="B2">
          <title>p16-unmethylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="12.0"/>
                    <measurement group_id="B2" value="57.9" spread="11.0"/>
                    <measurement group_id="B3" value="57.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia</title>
        <description>The follow-up examination was carried out with a 3-month interval. Re-biopsy was done as clinically indicated, e.g. the lesion recurs or has tendency for malignant development. Pathologic diagnosis was made by at least two pathologists without the knowledge of baseline p16 methylation, based on the World Health Organization's criteria, at Peking University School of Stomatology. The number of participants with malignant transformation of oral dysplasia was calculated based on the number of participants with oral dysplasia progressed to carcinoma by the end of the trial in each cohorts.</description>
        <time_frame>from 3 months to 124 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>p16-methylated</title>
            <description>patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.</description>
          </group>
          <group group_id="O2">
            <title>p16-unmethylated</title>
            <description>patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia</title>
          <description>The follow-up examination was carried out with a 3-month interval. Re-biopsy was done as clinically indicated, e.g. the lesion recurs or has tendency for malignant development. Pathologic diagnosis was made by at least two pathologists without the knowledge of baseline p16 methylation, based on the World Health Organization's criteria, at Peking University School of Stomatology. The number of participants with malignant transformation of oral dysplasia was calculated based on the number of participants with oral dysplasia progressed to carcinoma by the end of the trial in each cohorts.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cancer-free Survival Time for Patients With Oral Epithelial Dysplasia</title>
        <time_frame>from 3 months to 124 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants only got regular examinations during the followup period. No extra treatment was administrated.</desc>
      <group_list>
        <group group_id="E1">
          <title>p16-methylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.</description>
        </group>
        <group group_id="E2">
          <title>p16-unmethylated</title>
          <description>patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Department of Etiology</name_or_title>
      <organization>Peking University School of Oncology</organization>
      <phone>+8610-88196752</phone>
      <email>dengdajun@bjmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

